Leukocoria or new strabismus in a child needs urgent examination under anaesthesia, imaging and genetic counselling; an intraocular biopsy is not part of that pathway. In an adult, a pigmented choroidal mass is diagnosed clinically and with ultrasound, and a gene-expression class estimates metastatic risk without proving it.
Terminology and draft status
Terminology review is not complete. No new WHO UMD entry verification is claimed for this copy; pending entries and limits are recorded in terminology.md.
01The hierarchy: life, eye, vision
Prioritise life, then eye preservation, then vision. Suspected retinoblastoma needs prompt specialist assessment of intraocular and extraocular disease; uveal melanoma also requires a systemic risk and surveillance plan even when the eye can be preserved. 1 2 3
Two diseases, two clocks. Retinoblastoma is a paediatric emergency diagnosed mostly in the first years of life; delays of weeks can decide whether tumour leaves the eye. Uveal melanoma is an adult malignancy whose ocular treatment and metastatic surveillance run on separate timelines. One combined algorithm would blur both. 1 2 3
Diagnosis is mainly clinical and multimodal: slit-lamp and fundus examination, wide-field photography, B-scan and A-scan ultrasound, and OCT or autofluorescence where the macula or the pigment is in question. MRI answers a different question, namely extraocular, optic-nerve or intracranial disease. Histology is not the first step in a suspected retinoblastoma. 1 2 3
In a case presentation, give age and laterality, the observation that triggered referral, the measured size and location, the imaging question, and the next step. That sequence shows whether you have understood which disease you are dealing with before you name a treatment. 1 2 3
02Retinoblastoma: genetics, examination and the biopsy rule
Retinoblastoma is the most common intraocular tumour of childhood, and two-thirds of cases are diagnosed before age 2 years. The export's statement that diagnosis is usually made before age 5 is compatible with this, but the earlier peak matters clinically: a white pupil in an infant is never a reason to wait. 1 2
The genetic mechanism is biallelic inactivation of RB1 on chromosome 13q, the two-hit model. A first hit may be constitutional, in every cell, or somatic, confined to the retinal cell that becomes a tumour. The export lists 10% hereditary, 30% germline de novo and 60% somatic. Those three labels mix two different questions, namely whether there is a family history and where the first hit arose, so they are not mutually exclusive inheritance categories. 1 2
Current reference texts separate heritable from non-heritable disease instead: roughly 25% to 30% heritable and 70% to 75% non-heritable. Within heritable disease, about 25% of patients have an affected parent and about 75% carry a de novo germline variant. Those denominators differ from the export's 10/30/60 split, which should be read as a teaching approximation rather than an epidemiological rule. 2
Unilateral disease does not exclude a germline variant. About 15% of unilateral cases are presumed heritable. In one series of 482 patients, variants were found in 33% under 12 months, 6% at 12–24 months and 7% at 24–39 months; these are age-specific cohort estimates. Genetic counselling/testing guides family screening and surveillance for second primary cancers regardless of family history. 1 2
Presentation is usually leukocoria, sometimes first noticed on a flash photograph, with strabismus second and often reflecting macular involvement. Advanced eyes present with pain, glaucoma, buphthalmos or an orbital cellulitis-like picture. Any of these findings requires urgent referral to a centre that can examine the child under anaesthesia. 1 2
Examination under anaesthesia with a maximally dilated pupil and scleral indentation inspects the whole retina and documents the number, size and location of tumours, subretinal fluid and vitreous or subretinal seeds. In the anterior segment, look for tumour seeding into the anterior chamber, which can mimic a hypopyon, and for rubeosis iridis. 2
Ultrasound and MRI answer different questions. Intratumoural calcification with posterior shadowing is typical and supports the diagnosis, but it is not pathognomonic in every eye, and its absence does not exclude retinoblastoma. MRI assesses extrascleral, optic-nerve and intracranial disease; optic-nerve enhancement alone does not prove involvement. CT is avoided for surveillance because of radiation exposure in a child with a germline variant. 1 2
Do not plan an intraocular biopsy in a child with suspected retinoblastoma. The diagnosis is made clinically, and a needle track risks extraocular seeding and upstaging. Tissue is examined after enucleation by a pathologist experienced in ocular tumours, specifically to identify high-risk features such as massive choroidal invasion, scleral invasion or optic-nerve involvement beyond the lamina cribrosa. 1 2
The International Classification of Retinoblastoma groups eyes by seeding and by poor-prognosis features. Group A: tumours 3 mm or smaller, confined to the retina, further than 3 mm from the foveola and 1.5 mm from the optic disc. Group B: all remaining discrete retinal tumours, including those failing the group A size or location criteria, with subretinal fluid less than 3 mm from the tumour and no seeding. Group C: discrete tumour with local subretinal or vitreous seeding, for example seeding less than 3 mm from the tumour. Group D: diffuse disease with significant vitreous or subretinal seeding, which may include greasy seeds or subretinal plaques. Group E: any poor-prognosis feature, such as tumour touching the lens, tumour anterior to the anterior vitreous face, diffuse infiltrating disease, neovascular glaucoma, opaque media from haemorrhage, aseptic orbital cellulitis or phthisis bulbi. 1 2
Published versions of this classification are not word-for-word identical, and the differences are not trivial: in one analysis the two published schemas changed group assignment in 5.2% of eyes, and in 25% of group E eyes. When you quote a group, say which version and which findings you used. That is more honest than presenting the grouping as a fixed law. 4
Treatment is chosen by stage, laterality, germline status and the chance of useful vision. Enucleation is often the right operation for a group E eye with poor visual potential, but it is not automatic for every group E eye: a small subset can be salvaged at an experienced centre. Systemic chemotherapy, intra-arterial chemotherapy and intravitreal chemotherapy for seeds are options in selected eyes, treatment options following clinical diagnosis, and each has its own local and systemic risks. 1 2
Trilateral retinoblastoma is an asynchronous midline intracranial neuroblastic tumour, usually pineal and sometimes suprasellar. It is a separate primary tumour of the same germline predisposition, not an ordinary metastasis from the eye. Reported frequencies vary widely between series, from about 1% of all cases and 3% to 5% of bilateral cases in the older literature to 5% to 15% of heritable cases in current summary texts, so no single percentage should be taught as universal. 1 2 5
Surveillance after treatment follows germline status: frequent examinations while new tumours remain possible, and MRI screening for intracranial disease in heritable disease according to the centre's protocol. Survivors of heritable retinoblastoma also carry a lifelong risk of second primary cancers, which is one reason genetic counselling belongs to the initial management rather than to follow-up convenience. 1 2
03Uveal melanoma: diagnosis, prognosis and the choice of treatment
Uveal melanoma is the most common primary intraocular malignancy in adults. The export's figure of 5 to 11 cases per million is an international range; United States incidence is about 4.3 per million and other reporting countries range from about 5.3 to 10.9 per million, so the number is population-specific. It is not the most common intraocular malignancy overall, because choroidal metastasis is more frequent. 1 3
Spread is haematogenous because the uveal tract has no lymphatic channels, and the liver is the first site identified in most patients who metastasise. Only 2% to 3% of patients have detectable systemic metastasis at the time of ocular diagnosis, which is why the eye can look like a local problem while the real risk is systemic. 3
The typical tumour is a brown, dome-shaped subretinal mass, sometimes amelanotic. A mushroom or collar-button shape appears when the tumour breaks through Bruch membrane and expands beneath the retina; the original description that the retinal pigment epithelium holds the tumour back is a simplification, since the shape requires that the membrane has given way. Orange pigment on the surface reflects lipofuscin, and overlying subretinal fluid is common. 1 3
Ultrasound supports rather than proves the diagnosis: low internal reflectivity from dense cellular packing, a steep initial A-scan spike, choroidal excavation, and sometimes spontaneous vascular pulsations within the tumour. The export calls these pulsations the Kappa sign; I found no authoritative definition or origin for that eponym in the sources inspected, so the term is retained with a flag and without inventing an erratum. None of these signs, alone or together, replaces clinical judgement and follow-up. 1 3
A small indeterminate pigmented lesion may require serial imaging to distinguish a naevus from melanoma. Documented growth is useful, but a clinically convincing or high-risk melanoma should not automatically wait for growth; obtain ocular-oncology assessment. Differential diagnoses include naevus, haemangioma, metastasis and inflammatory masses. 1 3
Prognostic information comes from the tumour and, in selected centres, from tissue. Thickness and diameter, ciliary body involvement, extraocular extension and cell type matter; so do chromosome 3 loss, 8q gain and 6p changes, and the gene-expression profile. In a 2023 validation cohort, tumour thickness predicted metastasis better than gene-expression class, which is a reminder that a molecular result sits inside a clinical picture. 3 6 7
Class 2 and BAP1 loss mark a higher risk; they do not mean that metastasis is certain. In a prospective multicentre study, 5-year metastasis-free survival was 58.3% for class 2 tumours without PRAME expression and 44.8% with PRAME expression. Class 1 was not zero risk: 5-year metastasis-free survival was 95.6% for class 1 without PRAME and 80.6% with PRAME. The export's 55% at 5 years is a cohort-specific figure I could not verify in a primary report, so it is kept as a historical estimate, not a universal rate. 1 6 7
COOG2 prospectively followed1577 patients with choroidal/ciliary-body melanoma at26 North American centres. The95% confidence intervals for those four5-year metastasis-free estimates were51.1–66.4%,37.9–52.8%,93.9–97.4% and73.9–87.9%, respectively. These observational prognostic groups do not show that testing or more intensive surveillance improves survival; selection, follow-up and external calibration matter. 6
Treatment is selected by size, site, visual potential and centre expertise. Plaque brachytherapy with iodine-125 or ruthenium-106, proton beam therapy, enucleation and, in selected cases, local resection are all legitimate options; selected small indeterminate lesions may be observed under specialist supervision. The 85 Gy to the tumour apex quoted in the export is the iodine-125 prescription used in the Collaborative Ocular Melanoma Study, not a dose that transfers automatically to every isotope or every protocol. 1 3
Proton therapy is attractive for tumours close to the macula or optic disc because the dose can be shaped to stop beyond the target, but it is not guaranteed to be superior for every juxtapapillary tumour, and it is not available everywhere. In the medium-tumour trial, iodine-125 brachytherapy and enucleation produced equivalent mortality outcomes through 12 years, with 85% of irradiated eyes retained at 5 years and 37% of them seeing better than 20/200. 3
Plan metastatic surveillance with oncology, including liver imaging at centre-specific intervals. The treatment of metastatic uveal melanoma requires its own assessment of patient factors, tumour biology, current local indications and systemic evidence. 1 3
04Choroidal naevus: which spot needs watching
The export states that about 8% of the population has a choroidal naevus. Prevalence depends on the population and the imaging method: a German imaging study found posterior naevi in 3.1% of participants, or 2.6% after age standardisation, and estimated whole-fundus prevalence at 7.7% if only about 40% of naevi are captured by a macula-centred image. A Danish nationwide sample of 35559 people found 2.54%. The 8% figure is therefore a rough upper-range estimate, not a universal prevalence. 1 9 10
The clinical task is not to diagnose every naevus but to recognise the minority that is transforming. In the Danish sample, about 90.8% of detected naevi were graded common and 5.3% low risk, with 2.7% high risk and 1.2% probable melanoma under a modern grading system. Most spots therefore need documentation and comparison, not intervention. 10
The export's mnemonic, To Find Small Ocular Melanoma Using Helpful Hints Daily, is a heuristic from an older cohort era, and it is kept because it is still taught. It lists thickness greater than 2 mm, subretinal fluid, visual symptoms or photopsia, orange pigment, margin less than 3 mm from the optic disc, ultrasound hollowness with low internal reflectivity, and absence of a halo or drusen. Read the list as seven reasons to look again, not as a score that declares melanoma. 1 8
Two cautions matter. No single feature makes a melanoma: a 2 mm lesion with drusen may be a stable naevus, and a flat lesion with orange pigment may be melanoma. And drusen do not prove benignity; they suggest chronicity, while their absence is only a soft risk marker. Growth on serial imaging remains the most practical evidence of transformation. 1 3 8
Imaging frameworks such as MOLES organise lesion size, orange pigment, fluid and other features for referral and monitoring. A grading category is not a calibrated personal probability; use the centre’s named system consistently and document baseline findings. 8 10
Practical follow-up is unglamorous: wide-field photography, measurement of thickness on ultrasound, OCT for subretinal fluid, autofluorescence for orange pigment, and a written comparison with the previous visit. Refer when thickness increases, fluid appears, symptoms develop, orange pigment spreads or the margin approaches the disc. A stable, small, drusen-covered naevus does not need treatment. 1 8
05CHRPE: a flat lesion with a systemic question attached
CHRPE is a flat, sharply demarcated, hyperpigmented lesion of the retinal pigment epithelium, typically with one or more lacunae inside it. Because it is flat, it produces no elevation on ultrasound; the export's entry of no A-scan reflectivity is a shorthand for that absence of a mass, not a measured tissue signature. 1 14
A typical solitary CHRPE and benign grouped pigmentation described as bear tracks can occur without FAP. Describe the pattern and visual effects; do not infer an intestinal syndrome from either appearance alone. 14
Atypical multiple bilateral lesions raise a different question, particularly with a suggestive family history or other extracolonic features. GeneReviews lists multifocal/bilateral CHRPE among findings suggesting APC-associated polyposis and reports CHRPE in up to 80% of FAP; this does not make every grouped benign bear-track pattern a FAP diagnosis. 1 14
The export calls this Gardner syndrome. Current genetics texts treat Gardner syndrome as a historical label inside the familial adenomatous polyposis spectrum and advise against using it as a separate diagnosis. The clinical message survives the change in nomenclature: a suggestive ocular phenotype is a reason to ask about bowel polyps, osteomas, dental anomalies, desmoid tumours and family history, and to arrange genetics and gastroenterology assessment rather than to order a colonoscopy from the eye clinic alone. 14
Document what you saw: number of lesions, laterality, largest diameter, lacunae, and any change from previous imaging. Say explicitly whether the pattern is solitary-typical or multifocal-atypical, because that distinction is what the receiving colleague needs in order to decide how far to investigate. 1 14
06Vascular tumours and metastasis: the useful mimics
A circumscribed choroidal haemangioma is a red-orange, dome-shaped choroidal lesion with high internal reflectivity on A-scan and an acoustic-solid appearance. It may be asymptomatic for years; when it causes exudative detachment or macular oedema, vision falls. Diffuse choroidal haemangioma occurs in Sturge-Weber syndrome and behaves differently, with widespread choroidal thickening. 1 11
Treatment is for the symptomatic, exudative case. Photodynamic therapy is used for selected lesions with subretinal fluid, while transpupillary thermotherapy, laser photocoagulation, plaque brachytherapy and external radiotherapy are alternatives in other configurations. A tertiary-centre series managed 172 patients with several different modalities, which is a fair picture of the evidence: retrospective, modality-specific and selected, without a universal first choice. 11
A vasoproliferative tumour is a retinal vascular mass, often yellow-pink, that leaks and produces hard exudates, sometimes with a Coats-like response. It can be idiopathic or secondary to uveitis, retinal dystrophy or previous inflammation. The export's statement that there is no choroidal involvement is a useful orienting rule, not an absolute ultrasound criterion: small lesions and surrounding exudation can blur the boundary. 1 13
Selected vasoproliferative tumours are treated with cryotherapy, and larger or refractory lesions with plaque brachytherapy; a published series of 30 eyes treated with iodine-125 plaques reported regression in 29 eyes and resolution of exudative detachment in 15 of 23. Anti-VEGF agents are used as an adjunct for exudation, not as a universal cure, and the choice depends on size, location, exudation and prior treatment. 13
Choroidal metastasis is the most common intraocular malignancy overall. Breast and lung carcinomas account for most cases; the lesion is typically creamy yellow and placoid, and it is often multifocal or bilateral, but a unilateral solitary mass is entirely possible and must not be dismissed because it looks atypical. 1 12
When a choroidal metastasis is the first sign of cancer, the eye finding is only the beginning. The next step is coordinated staging with oncology to identify the primary, not an isolated ocular work-up. Ocular treatment, whether systemic therapy, radiotherapy, plaque brachytherapy or photodynamic therapy in selected cases, follows the systemic plan and the threat to vision. 12
07Synopsis: six entities, one table, three questions
The table keeps the export's six entities in their original order and its five columns: entity, localisation, A-scan reflectivity, specific signs and a practical point. Use it to organise recall, then return to the chapters for the limits that a table cannot carry. 1
Three questions sort almost any intraocular mass. Which layer is it in, retinal, choroidal or pigment epithelial? What does ultrasound add about reflectivity, height and internal structure? And what is the systemic context, namely age, laterality, family history and known malignancy? 1 2 3
Then document and refer with a question, not just a picture: measured size, location relative to fovea and disc, presence of fluid, seeds or calcification, and the specific uncertainty. A referral that states the question gets a better answer than one that states only the diagnosis. 1 2
Two anchors remain. In a child with suspected retinoblastoma, do not biopsy the eye; examine under anaesthesia, image, and involve genetics. In an adult with a pigmented choroidal lesion, imaging estimates risk and follow-up proves change, but neither replaces the other. Everything else in this lecture is detail arranged around those two sentences. 1 2 3
| Entity | Localisation | A-scan reflectivity | Specific signs | Practical point |
|---|---|---|---|---|
| Retinoblastoma | Retinal | Variable (calcification high) | Calcification, seeds | No biopsy. Examine siblings and arrange genetic counselling and testing, not sibling examination alone. |
| Uveal melanoma | Choroidal | Low | Mushroom shape, Kappa sign (eponym unresolved) | Class 2 or BAP1 loss means higher metastatic risk, not certain metastasis. |
| Choroidal naevus | Choroidal | High | Drusen (marker of chronicity, not proof of benignity) | Check the TFSOM-UHHD features; document and compare rather than treat. |
| Haemangioma | Choroidal | High | Orange-red, glows | Photodynamic therapy for selected symptomatic exudative cases, not for every lesion. |
| Metastasis | Choroidal | Medium to high | Bilateral, multifocal (unilateral and solitary are possible) | Search for the primary with oncology; breast and lung are frequent. |
| CHRPE | RPE | Flat (none) | Lacunae, sharp border | Multifocal, bilateral or atypical: genetics and gastroenterology assessment for FAP, not colonoscopy for every CHRPE. |
What are the main learning points of this lecture?
Retinoblastoma is diagnosed clinically under anaesthesia with ultrasound, MRI and genetics, and is never biopsied inside the eye. Uveal melanoma is diagnosed clinically and by ultrasound; molecular class estimates metastatic risk without proving it, and treatment is chosen by size, site and visual potential. Most choroidal naevi are stable, CHRPE is usually benign but multifocal or bilateral lesions raise the question of familial adenomatous polyposis, and choroidal metastasis may be the first sign of an unknown primary.
Which findings require urgent assessment?
Leukocoria, a white pupillary reflex or new strabismus in a child requires immediate specialist assessment. In adults, sudden visual loss, a rapidly growing intraocular mass, severe pain or a painful blind eye need urgent review. Suspected trilateral disease or extraocular extension also requires urgent multidisciplinary assessment.
References and access status
- 1Immutable original export: Umfassender Leitfaden zur okulären Onkologie (review 189 source snapshot)
Complete local export read 16 November 2026 at base commit 6a34697530d4d50260ad36b2c689ba4d4d100620: 34903 bytes, SHA-256 cad838ebdebcae9bdecab36447d7f543f4c628ddb588a4c06557e2f2bdee62bc, matching the supplied snapshot. All headings, paragraphs, list items, the six-row table, both questions, the patient panel and the single YouTube link were read, including the duplicated wrapper sections (Prüfungsorientierter Überblick, Diagnostik, Differenzialdiagnosen, Therapieprinzipien, Red Flags). The export names the source lecture '019_Umfassender Leitfaden zur okulären Onkologie' and the video 'Ocular Oncology Retinoblastoma, Uveal Melanoma, and Choroidal Nevi - Musa Abdelaziz, MD'; recording, transcript, speaker attribution and any speaker role are unchecked.
- 2NCI PDQ, Retinoblastoma Treatment (health professional version), latest update 3 April 2025
Selected sections read in the live NCI professional text on 16 November 2026: incidence, clinical presentation, diagnostic and staging evaluation, genetics and genomics, heritable and non-heritable disease, genetic counselling and testing, postdiagnosis surveillance, trilateral retinoblastoma, tumour pathology, the AJCC heritable-trait table, International Classification of Retinoblastoma Table 12, and the treatment-option overview. Selected text, not the complete PDQ summary: figures, most level-of-evidence statements, the full treatment sections and the reference list were not appraised, and no trial full report was read.
- 3NCI PDQ, Intraocular (Uveal) Melanoma Treatment (health professional version), latest update 16 May 2025
Selected sections read in the live NCI professional text on 16 November 2026: incidence and mortality, anatomy, diagnosis, prognostic factors, cellular classification, tumour size and COMS size boundaries, metastatic disease, AJCC staging tables, prognostic molecular features and the treatment-option overview including enucleation and iodine-125 brachytherapy outcomes. Selected text, not the complete summary: later treatment sections, figures and cited primary reports were not read.
- 4Novetsky et al. 2009, PMID 19172510: published ICRB definitions contain inconsistencies
Abstract read 16 November 2026 through the PubMed EFetch display. The study analysed 96 eyes and reported that differing published ICRB schemas changed group assignment in 5.2% of eyes and 25% of group E eyes. Full article and the two original schema documents were not read.
- 5de Jong et al. 2014, PMID 25126964: trilateral retinoblastoma systematic review and meta-analysis
Abstract read 16 November 2026 through the PubMed EFetch display. The abstract states that about 5% of children with germline RB1 mutation are at risk of trilateral retinoblastoma, and reports survival change after 1995. Full article, included-study data and the authors' exact incidence estimates were not read; the figure is not treated as a universal frequency.
- 6Harbour et al. 2024, PMID 39052972: 15-gene expression profile and PRAME, COOG2 prospective validation
Abstract read 16 November 2026 through the PubMed EFetch display: 1577 patients, 5-year metastasis-free survival 95.6% for class 1/PRAME-negative, 80.6% for class 1/PRAME-positive, 58.3% for class 2/PRAME-negative and 44.8% for class 2/PRAME-positive. Full article, supplementary methods and calibration data were not read; these are cohort estimates, not individual probabilities.
- 7Miguez et al. 2023, PMID 36739981: validation of gene-expression profiling in uveal melanoma
Abstract read 16 November 2026 through the PubMed EFetch display: retrospective three-centre cohort of 337 patients, tumour thickness a stronger prognostic factor than gene-expression class, observed 5-year metastasis-free survival 47.5% for class 2 tumours, and no difference between class 1A and 1B. Full article and complete multivariable model were not read.
- 8Shields et al. 2021, PMID 34003909: white paper on ophthalmic imaging for choroidal nevus
Abstract read 16 November 2026 through the PubMed EFetch display. The white paper describes clinical risk features and multimodal imaging for nevus transformation and the possible role of artificial intelligence. Full text, risk-factor tables and the underlying cohort analyses were not read, so no numeric risk per feature is quoted here.
- 9Lever et al. 2026, PMID 42469712: prevalence of choroidal naevi in Germany (BiDirect)
Abstract read 16 November 2026 through the PubMed EFetch display: 1170 participants aged 37 to 68 years, crude posterior naevus prevalence 3.1% (95% CI 2.1 to 4.1), age-standardised 2.6%, estimated whole-fundus prevalence 7.7% under a 40% detection assumption. Full article, imaging protocol and sensitivity analysis were not read.
- 10Faber et al. 2026, PMID 41789693: age distribution of choroidal nevi in 35559 individuals
Abstract read 16 November 2026 through the PubMed EFetch display: Danish nationwide optometry imaging, crude nevus prevalence 2.54% (95% CI 2.37 to 2.71), MOLES grading with 90.8% common, 5.28% low risk, 2.70% high risk and 1.17% probable melanoma. Full article, image grading protocol and longitudinal follow-up were not read.
- 11Koç et al. 2024, PMID 38955894: management of circumscribed choroidal haemangioma
Abstract read 16 November 2026 through the PubMed EFetch display: retrospective tertiary-centre series of 172 patients managed with observation, transpupillary thermotherapy, argon laser, photodynamic therapy, plaque brachytherapy or stereotactic radiosurgery; median follow-up 10 months. Full article, per-modality outcomes and selection criteria were not read, so no comparative efficacy is claimed.
- 12Nag 2026, PMID 42325542: intraocular and ocular adnexal metastases, a comprehensive review
Abstract read 16 November 2026 through the PubMed EFetch display: choroidal metastases as the most common intraocular presentation, breast and lung carcinomas as the most frequent primaries, haematogenous spread, and systemic therapy or radiotherapy as treatment cornerstones. Full review text and its primary references were not read.
- 13Cohen et al. 2008, PMID 18779485: iodine-125 plaque radiotherapy for vasoproliferative tumours of the retina
Abstract read 16 November 2026 through the PubMed EFetch display: 30 eyes, tumour regression in 29, complete resolution of exudative detachment in 15 of 23, visual acuity improved or stable in 22. Full article and complication details beyond the abstract were not read.
- 14GeneReviews, APC-Associated Polyposis Conditions (NBK1345), last update 12 May 2022
Selected passages read 16 November 2026 at the NCBI Bookshelf address: the summary, the diagnostic suggestive-findings list including multifocal or bilateral CHRPE, the CHRPE paragraph reporting occurrence in up to 80% of FAP and isolated lesions in the general population, and the nomenclature statement that Gardner syndrome is a historical term within the FAP spectrum. The full GeneReview, its tables and its reference list were not read.
Original lecture link
For patients
Two different diseases are described here. Retinoblastoma is a rare eye cancer of young children. It is treated in specialised centres and is curable in most children when it is found early. Uveal melanoma is a cancer of the pigmented layer inside the adult eye; the eye can often be treated, but the tumour can later spread to the liver, so regular follow-up matters.
Most spots at the back of the eye are harmless naevi, similar to a mole on the skin. Your eye specialist decides from photographs, ultrasound and sometimes other imaging whether a spot needs only observation or closer checks. Not every spot needs treatment, and not every flat pigmented patch is a sign of an intestinal disease.
Tell your eye team about a family history of eye cancer, bowel polyps or an inherited syndrome. Seek help immediately for a white pupil in a child, sudden loss of vision, severe eye pain or a fast-growing lump. This information explains general principles and cannot replace a personal examination, diagnosis or treatment recommendation.
Leukocoria, a white pupillary reflex or new strabismus in a child needs immediate specialist assessment. Sudden visual loss, a rapidly growing intraocular mass, severe pain or a painful blind eye also need urgent review. This text is teaching material and cannot replace an examination.